Alnylam kicks off #JPM18 with a restructured Sanofi deal, grabbing global rights to patisiran
Four years ago Alnylam $ALNY jazzed the start of the JPMorgan conference with news that Sanofi had stepped up to pay $700 million for a chunk of its stock and the right to expand its commercial rights to the biotech’s lead drug, patisiran. But with patisiran on the verge of winning likely regulatory approval this year, the companies have once again restructured their deal in a way that gives Alnylam global control over its future.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
